Nicholas Lintzeris1, Timothy B Mitchell, Alyson J Bond, Liam Nestor, John Strang. 1. National Addiction Centre, Institute of Psychiatry, Kings College London, and South London and Maudsley NHS Trust, P.O. Box 48, 4 Windsor Walk, Denmark Hill, London SE5 8AF, United Kingdom. nicholas.lintzeris@sswahs.nsw.gov.au
Abstract
BACKGROUND:Benzodiazepine abuse is common among methadone- and buprenorphine-maintained patients; however interactions between these drugs under high dose conditions have not been adequately examined under controlled conditions. OBJECTIVE: To investigate the effects of co-administering diazepam with methadone or buprenorphine under high dose conditions. DESIGN: Double-blind, randomly ordered, 2 x 2 cross-over design in which the effects of diazepam dose (0mg versus 40 mg) and opioid dose (100% versus 150% normal dose) were examined over four sessions in methadone- and buprenorphine-maintained patients. PARTICIPANTS: Four methadone- and seven buprenorphine-prescribed patients without concurrent dependence on other substances or significant medical co-morbidity. MEASURES: Physiological (pulse rate, blood pressure, pupil size, respiratory rate and peripheral SpO2), subjective (ARCI, VAS ratings) and performance (reaction time, cancellation task and Digit Symbol Substitution Test, DSST) measures were taken prior to and for 6h post-dosing. RESULTS: High dose diazepam was associated with time-dependent increases in the intensity of subjective drug effects (strength of drug effect, sedation) and decreases in psychological performance (reaction time, DSST) for both methadone and buprenorphine patients. These effects were generally independent of the opioid dose administered. High dose opioid administration (150% normal dose) was associated with reductions in overall SpO2 levels and performance (reaction time, DSST) in the methadone patients, but had virtually no impact on pharmacodynamic responses in the buprenorphine group. CONCLUSION: High dose diazepam significantly alters subjective drug responses and psychological performance in patients maintained on methadone andbuprenorphine.
RCT Entities:
BACKGROUND:Benzodiazepine abuse is common among methadone- and buprenorphine-maintained patients; however interactions between these drugs under high dose conditions have not been adequately examined under controlled conditions. OBJECTIVE: To investigate the effects of co-administering diazepam with methadone or buprenorphine under high dose conditions. DESIGN: Double-blind, randomly ordered, 2 x 2 cross-over design in which the effects of diazepam dose (0mg versus 40 mg) and opioid dose (100% versus 150% normal dose) were examined over four sessions in methadone- and buprenorphine-maintained patients. PARTICIPANTS: Four methadone- and seven buprenorphine-prescribed patients without concurrent dependence on other substances or significant medical co-morbidity. MEASURES: Physiological (pulse rate, blood pressure, pupil size, respiratory rate and peripheral SpO2), subjective (ARCI, VAS ratings) and performance (reaction time, cancellation task and Digit Symbol Substitution Test, DSST) measures were taken prior to and for 6h post-dosing. RESULTS: High dose diazepam was associated with time-dependent increases in the intensity of subjective drug effects (strength of drug effect, sedation) and decreases in psychological performance (reaction time, DSST) for both methadone and buprenorphinepatients. These effects were generally independent of the opioid dose administered. High dose opioid administration (150% normal dose) was associated with reductions in overall SpO2 levels and performance (reaction time, DSST) in the methadonepatients, but had virtually no impact on pharmacodynamic responses in the buprenorphine group. CONCLUSION: High dose diazepam significantly alters subjective drug responses and psychological performance in patients maintained on methadone and buprenorphine.
Authors: Bethea A Kleykamp; Ryan G Vandrey; George E Bigelow; Eric C Strain; Miriam Z Mintzer Journal: Am J Drug Alcohol Abuse Date: 2015-01-13 Impact factor: 3.829
Authors: R Kathryn McHugh; Victoria R Votaw; Olivera Bogunovic; Sterling L Karakula; Margaret L Griffin; Roger D Weiss Journal: Addict Behav Date: 2016-08-18 Impact factor: 3.913
Authors: Richard Hallinan; Séverine Crettol; Kingsley Agho; John Attia; Jacques Besson; Marina Croquette-Krokar; Robert Hämmig; Jean-Jacques Déglon; Andrew Byrne; John Ray; Andrew A Somogyi; Chin B Eap Journal: Eur J Clin Pharmacol Date: 2009-07-29 Impact factor: 2.953
Authors: Geoffrey R T Walton; Kanna Hayashi; Paxton Bach; Huiru Dong; Thomas Kerr; Keith Ahamad; M J Milloy; Julio Montaner; Evan Wood Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792